+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The effect of intravenous immunoglobulin on lymphocyte populations in children with Kawasaki syndrome



The effect of intravenous immunoglobulin on lymphocyte populations in children with Kawasaki syndrome



Clinical and Experimental Rheumatology 10(6): 617-620



High dose intravenous immunoglobulin (IVIG) is extremely effective therapy for Kawasaki syndrome (KS), but the mechanism of action remains unknown. The present study was performed to determine the effect of IVIG on lymphocyte populations and lymphocyte activation markers in 15 children with KS. Following IVIG, there was a decrease in the percentage of CD19 cells and an increase in the percentage of CD8 cells, but there was no change in the proportion of CD3 or CD4 cells. Moreover, there was no change in the percentage of activated CD4 or CD8 cells, as measured by HLA DR and interleukin-2 receptor expression after IVIG therapy. These results indicate that IVIG is effective treatment for KS via mechanisms other than the direct modulation of T cell activation markers.

(PDF emailed within 1 workday: $29.90)

Accession: 041625780

Download citation: RISBibTeXText

PMID: 1483316


Related references

The effect of intravenous immunoglobulin on lymphocyte populations and activation markers in kawasaki syndrome. Arthritis & Rheumatism 34(9 SUPPL): S121, 1991

Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease. Acta Paediatrica 90(6): 623-627, 2001

IL-1, IL-6 and TNFa activity in children with Kawasaki syndrome before and after treating with intravenous immunoglobulin. 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY [Author] The 9th International Congress of Immunology : 434, 1995

Lymphocyte hydrogen sulfide production predicts intravenous immunoglobulin resistance in children with Kawasaki disease: A preliminary, single-center, case-control study. Medicine 97(47): E13069, 2018

The Combined Usefulness of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting Intravenous Immunoglobulin Resistance with Kawasaki Disease. Journal of Pediatrics 178: 281-284.E1, 2016

Increasing Rate Of Intravenous Immunoglobulin Nonresponders Among Children With Acute Kawasaki Syndrome In San Diego County. Journal of Investigative Medicine 55(1): S122-S123, 2007

Effect of intravenous immunoglobulin on neutrophil counts in children with Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi 12(12): 991-992, 2016

Values of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting sensitivity to intravenous immunoglobulin in Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi 19(4): 410-413, 2017

A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease. Plos One 12(5): E0176957, 2017

The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease. Oncotarget 8(2): 2044-2052, 2016

Association of Neutrophil/Lymphocyte Ratio With Intravenous Immunoglobulin Treatment in Children With Guillain-Barré Syndrome. Journal of Child Neurology 33(2): 164-167, 2018

Neutrophil-to-Lymphocyte Ratio Predicts Intravenous Immunoglobulin-Resistance in Infants Under 12-Months Old With Kawasaki Disease. Frontiers in Pediatrics 7: 81, 2019

Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Journal of Acquired Immune Deficiency Syndromes 6(10): 1103-1113, 1993

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?. Korean Circulation Journal 47(2): 179-181, 2017

Intravenous immunoglobulin in Kawasaki syndrome: a progress report. Pediatric Infectious Disease 5(3 Suppl.): S211-S215, 1986